Plasma pTau181 enhances the prediction of future clinical decline in amyloid-positive mild cognitive impairment.

ABSTRACT:

Abstract

Plasma pTau181, a marker of amyloid and tau burden, was evaluated as a prognostic predictor of clinical decline and Alzheimer's disease (AD) progression of amyloid-positive (Aβ+) patients with mild cognitive impairment (MCI). The training cohort for constructing the Bayesian prediction models comprised 135 Aβ+ MCI clinical trial placebo subjects. Performance was evaluated in two validation cohorts. An 18-month ≥1 increase in the Clinical Dementia Rating Sum of Boxes was the clinical decline criterion. Baseline plasma pTau181 concentration matched clinical assessments' prediction performance. Adding pTau181 to clinical assessments significantly improved the prediction of an 18-month clinical decline and the 36-month progression from Aβ+ MCI to AD. The area under the receive

SUBMITTER: Devanarayan V 

PROVIDER: S-EPMC11263975 | biostudies-literature | 2024 Jul-Sep

REPOSITORIES: biostudies-literature